[PDF] Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group). | Semantic Scholar


    
    Skip to search formSkip to main content>



Semantic Scholar's Logo
Search




Sign InCreate Free Account


You are currently offline. Some features of the site may not work correctly.

	DOI:10.1200/jco.2012.30.5_suppl.373

Corpus ID: 45953846Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).
@article{Hutson2012PhaseIS,
  title={Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).},
  author={Thomas E. Hutson and L. Dang and R. Lauer and A. Starodub and R. Hauke and T. Logan and K. Bylow and M. Galsky and David C. Bibby and G. Kremmidiotis and E. Doolin and Tina C. Lavranos and Annabell F. Leske and N. Hahn and G. Sonpavde and C. Sweeney and J. Sarantopoulos},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 5_suppl},
  pages={373}
}
	Thomas E. Hutson, L. Dang, +14 authors J. Sarantopoulos
	Published 2012
	Medicine
	Journal of clinical oncology : official journal of the American Society of Clinical Oncology

373 Background: BNC105P is a Vascular Disruption Agent (VDA) that destabilizes tubulin polymers leading to selective damage of tumor vasculature, hypoxia and associated tumor necrosis. BNC105P also has a direct anti-proliferative action on cancer cells. Up regulation of the mTOR pathway has been identified as a survival response by the tumor to hypoxic insult. Preclinical investigations demonstrated that BNC105P is effective at selectively damaging the vasculature in primary and metastatic… Expand

View on PubMed
bionomics.com.au





Save to Library
Create Alert
Cite
Launch Research Feed





Share This Paper

2 Citations
View All









Topics from this paper


	BNC 105P
	everolimus
	Metastatic Renal Cell Cancer
	sunitinib
	Neoplasms
	Renal Cell Carcinoma
	Tyrosine Kinase Inhibitors [MoA]


	Hypoxia
	Epithelial cell of renal tubule
	Thrombocytopenia
	Adverse reaction to drug
	Kidney Neoplasm
	tumor necrosis
	Anemia


	Inflammatory disease of mucous membrane
	cancer cell
	DLST wt Allele
	Protein Tyrosine Kinase
	Vascular Diseases
	Milligram per Square Meter






2 Citations



Citation Type
Citation Type

	All Types
	Cites Results
	Cites Methods
	Cites Background






Has PDF
Publication Type


Author


More Filters
More Filters
Filters

Sort by Relevance
Sort by Most Influenced Papers
Sort by Citation Count
Sort by Recency






Combination therapy in metastatic renal cell cancer.
	A. Ravaud, M. Gross-Goupil, J. Bellmunt
	Medicine
	Seminars in oncology
	2013

	18



Save
Alert
Research Feed




Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
	S. Zhou, Liangdan Tang, +5 authors R. Berkowitz
	Medicine
	Gynecologic oncology
	2013

	8



Save
Alert
Research Feed








References



Molecular Cancer Therapeutics: From Bench to Bedside
	D. V. Hoff
	Biology
	2001

	49



Save
Alert
Research Feed








Related Papers

















	Abstract
	Topics
	2 Citations
	1 References
	Related Papers







Stay Connected With Semantic Scholar
Sign Up

About Semantic Scholar
Semantic Scholar is a free, AI-powered research tool for scientific literature, based at the Allen Institute for AI.
Learn More →

Resources
DatasetsSupp.aiAPIOpen Corpus
Organization
About UsResearchPublishing PartnersData Partners
 
FAQContact



Proudly built by AI2 with the help of our Collaborators
Terms of Service•Privacy Policy

The Allen Institute for AI


By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE